View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 30, 2019updated 12 Jul 2022 12:27pm

Immunicum reports positive results from Phase II MERECA trial

Immunicum has reported positive results from Phase II Metastatic Renal Cell Carcinoma (MERECA) trial, which evaluated the therapeutic impact of combining ilixadencel with sutent (sunitinib).

Immunicum has reported positive results from Phase II Metastatic Renal Cell Carcinoma (MERECA) trial, which evaluated the therapeutic impact of combining ilixadencel with sutent (sunitinib).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The combination of ilixadencel and sutent achieved complete tumour responses in five out of 45 evaluable metastatic kidney cancer patients (11%) compared to one out of 25 in the sutent monotherapy control arm (4%).

Immunicum said that the trial did not achieve the median overall survival rate due to extended patient survival of above 60% in both the treatment and control study arms at 18 months.

The exploratory, international, randomised, controlled and open-label Phase II trial MERECA enrolled a total of 88 newly diagnosed, intermediate and poor-prognosis metastatic renal cancer patients.

The trial’s primary objectives were to evaluate median overall survival (OS) and 18-month survival rates.

Evaluation of safety and tolerability, tumour response and immunological profiling, including T-cell infiltration were the secondary objectives of the trial.

Based on these trial results, the company plans to continue further studies on the development of ilixadencel in kidney cancer and other solid tumour indications.

Immunicum CEO Carlos de Sousa said: “Our main objective for MERECA was to explore the therapeutic benefit of ilixadencel in combination with a standard treatment regimen.

“The surprising number of complete responses in advanced-stage cancer patients is particularly encouraging and highly supportive of our vision for ilixadencel as a backbone therapy in modern cancer treatment regimens.”

According to the company, the overall safety and tolerability results were similar in both the treatment groups and are in line with previous clinical trials data for ilixadencel.

MERECA investigator Dr Magnus Lindskog said: “As a clinical oncologist specialised in treating kidney cancer patients, the prospect of an immune primer that can support the achievement of complete responses in advanced-stage patients with a positive tolerability and safety profile is extremely exciting, especially in an indication in which complete responses are rare.”

In August 2017, the company started patient enrolment for Phase II MERECA clinical trial and ended the enrolment last January.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena